17-n-n-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one and Hyperplasia

17-n-n-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one has been researched along with Hyperplasia* in 1 studies

Other Studies

1 other study(ies) available for 17-n-n-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one and Hyperplasia

ArticleYear
Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate.
    The Journal of steroid biochemistry and molecular biology, 1996, Volume: 59, Issue:5-6

    The expression of 5alpha-reductase type 1 and type 2 isoenzymes in hyperplastic human prostate tissue and several human prostate cell lines was investigated by Northern blot analyses, reverse transcription-polymerase chain reaction (RT-PCR), and enzyme activity. Separation of stroma and epithelium was confirmed histologically and only preparations with no apparent contamination were employed in the subsequent studies. Poly(A)+ RNA was isolated from stromal and epithelial fractions and analysed by Northern blot and RT-PCR. Inhibition of epithelial and stromal 5alpha-reductase activities by 17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan- 3-one (4MA) was assessed using a range of concentrations between 10(-13) and 10(-5) M. Results from Northern blot analyses and RT-PCR showed that the prostate stroma expressed 5alpha-reductase type 1 and type 2 isoenzymes, whereas the prostate epithelium only expressed 5alpha-reductase type 1. This was consistent with biphasic inhibition of 5alpha-reductase activity by 4MA in stroma and monophasic inhibition in epithelium. Cultured epithelial cells derived from human prostate only expressed 5alpha-reductase type 1 and had Vmax and Km values that approximated the lower end of the range reported for surgically removed prostate epithelium. The foregoing data explains the disparate activities of 5alpha-reductase, previously reported, in stroma and epithelium. The differential localization of these isoenzymes in the prostate suggests that future therapy of androgen-sensitive disease may be more successful through the use of selective inhibitors of the different 5alpha-reductase isoenzymes.

    Topics: Aged; Androgen Antagonists; Azasteroids; Blotting, Northern; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Epithelium; Gene Expression Regulation, Enzymologic; Humans; Hyperplasia; Isoenzymes; Kinetics; Male; Middle Aged; Oxidoreductases; Polymerase Chain Reaction; Prostate; Prostatic Neoplasms; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured

1996